⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ABOS News
Acumen Pharmaceuticals, Inc. Common Stock
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
globenewswire.com
ABOS
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
globenewswire.com
ABOS
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
globenewswire.com
ABOS
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
globenewswire.com
ABOS
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
globenewswire.com
ABOS
Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors
globenewswire.com
ABOS
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
globenewswire.com
ABOS
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
globenewswire.com
ABOS